A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2006
12/19/2006	US7151082 Administering an effective amount of an antagonist or inhibitor of high mobility group 1 protein (HMG1) for therapy of condition characterized by activation of the inflammatory cytokine cascade
12/19/2006	US7150984 Attenuated human rotavirus vaccine
12/19/2006	US7150983 Modified proteolytic enzyme for treatment of osteoarthritis
12/19/2006	US7150971 Membrane-resident steroid receptors and methods of use thereof
12/19/2006	US7150885 Preventives/remedies for infection, anti-endtoxin agents, vaccine adjuvants and growth promoters
12/19/2006	US7150875 Recombinant Plasmodium vivax merozoite protein-1 p42 vaccine
12/19/2006	US7150874 NUCLEIC ACID SEQUENCE USEFUL FOR INSERTION VIA HOMOLOGOUS RECOMBINATION; recombinant poxviruses carrying heterologous coding sequences transferred by DNA vector
12/19/2006	US7150873 Hydrophilic eimeria polypeptide; genetic engineering
12/19/2006	US7150872 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability
12/19/2006	US7150871 Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6
12/19/2006	US7150869 Gene therapy; cytokine complex; anticancer agent
12/19/2006	CA2251058C Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone h1
12/19/2006	CA2194761C Immunomodulatory oligonucleotides
12/19/2006	CA2145064C Improvements in or relating to immune response modification
12/14/2006	WO2006133450A2 Anti-cd19 antibody therapy for the transplantation
12/14/2006	WO2006133286A2 Treatment of tnf antagonist-resistant inflammatory disorders and related methods
12/14/2006	WO2006133271A2 Compositions and methods relating to target-specific photodynamic therapy
12/14/2006	WO2006133196A1 Modulation of cholesteryl ester transfer protein (cetp) activity
12/14/2006	WO2006133164A2 Anti-trkb monoclonal antibodies and uses thereof
12/14/2006	WO2006133148A2 Method of producing antibodies with modified fucosylation level
12/14/2006	WO2006132966A2 Webbed hiv envelope immunogens, methods for production and use of same
12/14/2006	WO2006132963A2 Modulation of microbial pathogen-host cell interactions
12/14/2006	WO2006132944A2 Probiotic system for aquaculture
12/14/2006	WO2006132907A2 Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
12/14/2006	WO2006132607A1 Mutant allergen(s)
12/14/2006	WO2006132605A2 Porcine circovirus type 2 vaccines
12/14/2006	WO2006132587A1 Tumour marker in brca2 associated breast cancer
12/14/2006	WO2006132363A1 Stabilizer for protein preparation comprising meglumine and use thereof
12/14/2006	WO2006132352A1 Pharmaceutical composition containing sc(fv)2
12/14/2006	WO2006132341A1 sc(Fv)2 SITE-DIRECTED MUTANT
12/14/2006	WO2006132251A1 Prophylactic/therapeutic agent for adult t cell leukemia
12/14/2006	WO2006131953A2 Antibodies directed against the myelin basic protein recognising an epitope of cd64 and their use as immunosuppressants
12/14/2006	WO2006131952A1 Novel analgesic treatment with prolonged effect
12/14/2006	WO2006131951A2 MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
12/14/2006	WO2006131936A2 Hepatitis c virus vaccine
12/14/2006	WO2006131752A1 Live and subunit vaccines
12/14/2006	WO2006131562A2 Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases
12/14/2006	WO2006131512A2 Anti-thrombotic agents
12/14/2006	WO2006131023A1 Polyinosinic acid-polycytidylic acid-based adjuvant
12/14/2006	WO2006131013A2 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
12/14/2006	WO2006116380A3 Plasma or serum fraction for the treatment or prevention of bacterial infections
12/14/2006	WO2006113470A3 Cancer treatment by combined inhibition of proteasome and telomerase activities
12/14/2006	WO2006111776A3 Pharmaceutical composition comprising serum obtained from a naive mammal
12/14/2006	WO2006109300A9 Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
12/14/2006	WO2006109071A3 Vaccine against burkholderia infections
12/14/2006	WO2006105168A3 Enhancing immune responses with bacterial exotoxins
12/14/2006	WO2006100257A3 Vaccine and antibodies against parasitic nematodes
12/14/2006	WO2006099175A3 Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
12/14/2006	WO2006096970A8 Synthetic anti-candida albicans oligosaccharide based vaccines
12/14/2006	WO2006094673A3 Synergistic mixtures of c6- to c12-alkanedi0ls and tropolone (derivatives)
12/14/2006	WO2006085961A3 Anti-mcp-1 antibodies, compositions, methods and uses
12/14/2006	WO2006084179A3 Hiv tat-cd4 hybried molecules and methods of use thereof
12/14/2006	WO2006065940A3 Identification and use of prognostic and predictive markers in cancer treatment
12/14/2006	WO2006046017A8 Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter
12/14/2006	WO2006016380A3 A chimeric g protein based rabies vaccine
12/14/2006	WO2005074986A3 Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
12/14/2006	WO2004006861A3 Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
12/14/2006	WO2001022972A9 Immunostimulatory nucleic acids
12/14/2006	US20060282909 Methods and compositions for therapeutic intervention in cardiac hypertrophy
12/14/2006	US20060282908 Identification of the genetic determinants of the polymorphic CYP3A5 expression
12/14/2006	US20060281902 Human signal peptide-containing proteins
12/14/2006	US20060281887 (Meth)acrylate copolymer for use as medical carrier
12/14/2006	US20060281697 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia
12/14/2006	US20060281679 Human FGF-23 gene and gene expression products
12/14/2006	US20060281149 Transforming growth factor-beta-related molecules and uses thereof
12/14/2006	US20060281146 Novel compositions and methods for the treatment of immune related diseases
12/14/2006	US20060281130 Metod of modulation of interaction between receptor and ligand
12/14/2006	US20060281128 Compositions and methods using lentivirus-based vectors for generating immune responses
12/14/2006	US20060281081 Method of diagnosing colon and gastric cancers
12/14/2006	US20060281072 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
12/14/2006	US20060280813 Pharmaceutical compositions containing bulbophyllum and their use for treating illnesses
12/14/2006	US20060280798 Nanoparticles for delivery of a pharmacologically active agent
12/14/2006	US20060280759 Live and subunit vaccines
12/14/2006	US20060280758 Modified vaccinia ankara virus variant
12/14/2006	US20060280757 Flavivirus vaccine delivery system
12/14/2006	US20060280756 Novel composition
12/14/2006	US20060280755 Modulation of NKG2D
12/14/2006	US20060280754 Especially arenaviruses, coronaviruses, filoviruses, orthomyxoviruses, paramyxoviruses, and retroviruses
12/14/2006	US20060280752 Peptide epitope-based vaccine for treating Herpes Simplex Virus infections and related diseases
12/14/2006	US20060280751 Method for enhancing efficacy of preparation of monoclonal antibody
12/14/2006	US20060280750 Anti-idiotypic antibodies which recognise the idiotope of an antibody specific for a yeast killer toxin possess microbicidal activity
12/14/2006	US20060280749 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
12/14/2006	US20060280748 Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
12/14/2006	US20060280747 capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, edema, inflammation
12/14/2006	US20060280746 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents
12/14/2006	US20060280745 Prion inhibition
12/14/2006	US20060280744 Methods for treating demyelination disorders
12/14/2006	US20060280743 Immunoglobulin for treatment of alzheimer's diseases
12/14/2006	US20060280742 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis
12/14/2006	US20060280741 Administering the antibody concurrently with an antagonist of IL-1 alpha to treat psoriatic arthritis; arthritis nodosa; seronegative spondylarthropathy, and ulcerative colitis
12/14/2006	US20060280740 Compositions and methods for regulating NK cell activity
12/14/2006	US20060280739 Novel human beta-2 integrin alpha subunit
12/14/2006	US20060280738 Anti-CD19 antibody therapy for transplantation
12/14/2006	US20060280737 Reducing body weight or food intake ; binding to antibody
12/14/2006	US20060280736 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280735 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/14/2006	US20060280734 Retargeting
12/14/2006	US20060280733 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
12/14/2006	US20060280732 To suppress apoptotic pathways by inhibiting cytochrome c-mediated caspase activation; inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorder
12/14/2006	US20060280728 Trimeric OX40-immunoglobulin fusion protein and methods of use

1 ... 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 ... 1823